Osmotica going down to Georgia with R&D/manufacturing operations; Aciex Therapeutics secures $8M;

@FierceBiotech: VC groups proffer $14.4M to back Yaupon's lymphoma drug app. Item | Follow @FierceBiotech

@JohnCFierce: This is pretty cool. Blurring electronics and biology, Air Force and NSF create light "smart skin." Piece | Follow @JohnCFierce

@RyanMFierce: Osmotica Pharma is heading down to Georgia, putting R&D/manufacturing facility in Marietta Story | Follow @RyanMFierce

@MaureenFierce: Dendreon's a Broken IPO, Again. News | Follow @MaureenFierce

> Aciex Therapeutics, a Westborough, MA-based developer of drugs for eye diseases, has brought in $8 million in equity financing. News

> Osmotica Pharmaceutical plans to open an R&D and manufacturing facility in Marietta, GA, bring 156 jobs to the site over a 5-year period. Report

> Norwegian firm Pronova BioPharma says that it's asked U.K. regulators for permission to advance its lead omega-3 fatty acid derivative, PRC-4016, in a Phase I clinical trial. Item

And Finally... A broader mandate for meningitis vaccination in Texas is ruffling some conservative feathers. Report

Pharma News

@FiercePharma: 90% of surveyed MDs know about Incivek and Victrelis. Majority prescribe both. Report #sermosurveys | Follow @FiercePharma

> Turkish private equity fund eyes stake in Bilim Ilac. News

> AZ to pay $2.5M in Idaho Medicaid case. Article

> Reuters: J&J chief gets president's ear on job growth. Report

> Pfizer reports "potentially improper payments" to feds. Story

> Time for Merck workers to sign for early retirement--or not. More

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.